We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Amgen Inc (AMGN) Ordinary US $ 0.01

Sell:$260.00 Buy:$266.50 Change: $2.19 (0.84%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$260.00
Buy:$266.50
Change: $2.19 (0.84%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$260.00
Buy:$266.50
Change: $2.19 (0.84%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Contact details

Address:
One Amgen Center Drive
THOUSAND OAKS
91320
United States
Telephone:
+1 (805) 4471000
Website:
https://www.amgen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AMGN
ISIN:
US0311621009
Market cap:
$139.10 billion
Shares in issue:
537.53 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
Dow Jones Industrial Average

Key personnel

  • Robert Bradway
    Chairman of the Board, President, Chief Executive Officer
  • Peter Griffith
    Chief Financial Officer, Executive Vice President
  • David Reese
    Executive Vice President, Chief Technology Officer
  • James Bradner
    Executive Vice President, Research and Development, and Chief Scientific Officer
  • Jonathan Graham
    Executive Vice President, General Counsel, Secretary
  • Murdo Gordon
    Executive Vice President - Global Commercial Operations
  • Esteban Santos
    Executive Vice President - Operations
  • Nancy Grygiel
    Senior Vice President, Chief Compliance Officer
  • Derek Miller
    Senior Vice President of Human Resources
  • Rachna Khosla
    Senior Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.